Comparing Lucid Diagnostics (NASDAQ:LUCD) and enVVeno Medical (NASDAQ:NVNO)

Lucid Diagnostics ( NASDAQ:LUCD – Get Your Free Report ) and enVVeno Medical ( NASDAQ:NVNO – Get Your Free Report ) are both small-cap medical companies, but which is the better business? We’ll compare the two businesses based on their valuation strength, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

return

This table compares Lucid Diagnostics and enVVeno Medical’s net margins, return on equity and return on assets.

Rating and Earnings

This table compares Lucid Diagnostics and enVVeno Medical’s gross revenue, earnings per share (EPS) and valuation.

enVVeno Medical has lower revenue, but higher revenue than Lucid Diagnostics. enVVeno Medical is trading at a lower price-to-earnings ratio than Lucid Diagnostics, indicating that it is currently the more affordable of the two stocks.

Institutional and insider ownership

74.0% of Lucid Diagnostics shares are owned by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are held by institutional investors. 8.8% of Lucid Diagnostics shares are held by company insiders. Comparatively, 17.0% of enVVeno Medical shares are held by company insiders. Strong institutional ownership is an indication that big money managers, endowments and hedge funds believe the stock is poised for long-term growth.

Analyst recommendations

This is a breakdown of recent ratings for Lucid Diagnostics and enVVeno Medical, provided by MarketBeat.

Lucid Diagnostics currently has a consensus target price of $3.94, indicating a potential upside of 402.36%. Given Lucid Diagnostics’ higher possible upside, equities analysts plainly believe Lucid Diagnostics is more favorable than enVeno Medical.

Risk and volatility

Lucid Diagnostics has a beta of 1.47, meaning its share price is 47% more volatile than the S&P 500. Comparatively, enVeno Medical has a beta of 1.21, meaning its share price is 21% more volatile than the S&P 500.

Summary

Lucid Diagnostics beats enVeno Medical in 9 of the 13 factors compared between the two stocks.

About Lucid Diagnostics

(Get a free report)

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostic technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily the highly lethal esophageal adenocarcinoma. Its flagship product, the EsoGuard Esophageal DNA Test, performed on samples collected with the EsoCheck Esophageal Cell Collection Device, a testing tool aimed at preventing EAC deaths by early detection of esophageal precancer in patients at risk of GERD. The company was founded in 2018 and is headquartered in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

About enVeno Medical

(Get a free report)

enVVeno Medical Corporation (Nasdaq: NVNO) is a medical device company focused on developing innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s flagship product, VenoValve®️, is a first-in-class surgical implant developed for the treatment of severe chronic deep venous insufficiency (CVI). Deep venous CVI occurs when the valves inside the deep veins of the leg are damaged, causing insufficient blood to return to the heart. Faulty venous valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure in the leg veins (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin wounds) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and functions as a replacement venous valve designed to reduce venous reflux and hypertension and restore proper directional blood flow back to the heart. With severe deep venous CVI affecting approximately 2.4 million people in the US who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the US Food and Drug Administration and is currently being evaluated in the US SAVVE clinical trial .

Receive daily news and reviews for Lucid Diagnostics – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Lucid Diagnostics and related companies with MarketBeat.com’s FREE daily email newsletter.